Arjun Agarwal Sells 1,587 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 1,587 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $80.95, for a total value of $128,467.65. Following the sale, the senior vice president owned 15,312 shares of the company’s stock, valued at approximately $1,239,506.40. The trade was a 9.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.69, for a total value of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.72, for a total value of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The stock was sold at an average price of $59.07, for a total value of $607,830.30.

Oruka Therapeutics Stock Up 18.0%

Shares of ORKA traded up $13.04 during mid-day trading on Monday, hitting $85.38. The company’s stock had a trading volume of 4,200,226 shares, compared to its average volume of 1,048,601. Oruka Therapeutics, Inc. has a one year low of $10.77 and a one year high of $91.00. The stock’s 50-day moving average is $65.16 and its two-hundred day moving average is $45.89.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. As a group, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Institutional Trading of Oruka Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new position in Oruka Therapeutics in the second quarter worth about $28,000. BNP Paribas Financial Markets boosted its holdings in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after purchasing an additional 2,306 shares in the last quarter. Royal Bank of Canada boosted its holdings in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Oruka Therapeutics in the 4th quarter valued at approximately $37,000. Finally, PNC Financial Services Group Inc. bought a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $39,000. Institutional investors own 56.44% of the company’s stock.

Wall Street Analysts Forecast Growth

ORKA has been the topic of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Oruka Therapeutics in a research note on Wednesday, June 3rd. BTIG Research reaffirmed a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a report on Thursday, May 14th. UBS Group raised their price objective on Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Finally, Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a report on Thursday, April 30th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.30.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.